1-9 of 9
Russell Z. Szmulewitz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)

Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang, Channing J. Paller, Joel Picus, Zachery R. Reichert, Russell Z. Szmulewitz, Scott T. Tagawa, Timothy M. Kuzel, Latifa A. Bazzi, Stephanie Daignault-Newton, Young E. Whang, Robert Dreicer, Ryan D. Stephenson, Matthew B. Rettig, Daniel Shevrin, Travis Gerke, Arul M. Chinnaiyan, Emmanuel S. Antonarakis
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4318–4328.
https://doi.org/10.1158/1078-0432.CCR-24-1402
Published: 01 October 2024
View articletitled, Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Open the PDF for Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer

Kunal B. Desai, Anthony V. Serritella, Walter M. Stadler, Peter H. O'Donnell, Randy F. Sweis, Russell Z. Szmulewitz
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2384–2392.
https://doi.org/10.1158/1078-0432.CCR-23-3636
Published: 03 June 2024
View articletitled, A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1929–1937.
https://doi.org/10.1158/1078-0432.CCR-22-3233
Published: 15 May 2023
View articletitled, PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer
Open the PDF for PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J. Small, Terence Friedlander, Lawrence Fong, Pamela L. Paris, Charles J. Ryan, Russell Z. Szmulewitz, Rahul Aggarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1531–1539.
https://doi.org/10.1158/1078-0432.CCR-21-4302
Published: 14 April 2022
View articletitled, A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

Anthony V. Serritella, Daniel Shevrin, Elisabeth I. Heath, James L. Wade, Elia Martinez, Amanda Anderson, Joseph Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M. Stadler, Russell Z. Szmulewitz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1549–1559.
https://doi.org/10.1158/1078-0432.CCR-21-4049
Published: 14 April 2022
View articletitled, Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide

Landon C. Brown, Susan Halabi, Joseph D. Schonhoft, Qian Yang, Jun Luo, David M. Nanus, Paraskevi Giannakakou, Russell Z. Szmulewitz, Daniel C. Danila, Ethan S. Barnett, Emily A. Carbone, Jimmy L. Zhao, Patrick Healy, Monika Anand, Audrey Gill, Adam Jendrisak, William R. Berry, Santosh Gupta, Simon G. Gregory, Richard Wenstrup, Emmanuel S. Antonarakis, Daniel J. George, Howard I. Scher, Andrew J. Armstrong
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 4077–4088.
https://doi.org/10.1158/1078-0432.CCR-20-3471
Published: 15 July 2021
View articletitled, Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Open the PDF for Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers

Himisha Beltran, Clara Oromendia, Daniel C. Danila, Bruce Montgomery, Christopher Hoimes, Russell Z. Szmulewitz, Ulka Vaishampayan, Andrew J. Armstrong, Mark Stein, Jacek Pinski, Juan M. Mosquera, Verena Sailer, Rohan Bareja, Alessandro Romanel, Naveen Gumpeni, Andrea Sboner, Etienne Dardenne, Loredana Puca, Davide Prandi, Mark A. Rubin, Howard I. Scher, David S. Rickman, Francesca Demichelis, David M. Nanus, Karla V. Ballman, Scott T. Tagawa
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (1): 43–51.
https://doi.org/10.1158/1078-0432.CCR-18-1912
Published: 03 January 2019
View articletitled, A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Open the PDF for A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers in another window
Includes: Supplementary data
Journal Articles

MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease

Raj R. Bhanvadia, Calvin VanOpstall, Hannah Brechka, Nimrod S. Barashi, Marc Gillard, Erin M. McAuley, Juan Manuel Vasquez, Gladell Paner, Wen-Ching Chan, Jorge Andrade, Angelo M. De Marzo, Misop Han, Russell Z. Szmulewitz, Donald J. Vander Griend
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3668–3680.
https://doi.org/10.1158/1078-0432.CCR-17-3673
Published: 31 July 2018
View articletitled, MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease
Open the PDF for MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease in another window
Includes: Supplementary data
Journal Articles

Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens

Won Kim, Li Zhang, John H. Wilton, Gerald Fetterly, James L. Mohler, Vivian Weinberg, Allison Morse, Russell Z. Szmulewitz, Terence W. Friedlander, Lawrence Fong, Amy M. Lin, Andrea L. Harzstark, Arturo Molina, Eric J. Small, Charles J. Ryan
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6269–6276.
https://doi.org/10.1158/1078-0432.CCR-14-1595
Published: 14 December 2014
View articletitled, Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens
Open the PDF for Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens in another window
Includes: Supplementary data